Condition
Raynaud Syndrome
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Not Yet Recruiting2
Completed1
Terminated1
Withdrawn1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07240649Phase 4Not Yet Recruiting
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT03869008Not ApplicableTerminated
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
NCT05698979Phase 3Not Yet Recruiting
Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease
NCT04898036Not ApplicableWithdrawn
Phototherapy For Treatment Of Raynaud's Phenomenon
NCT01291199Phase 2CompletedPrimary
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
Showing all 5 trials